Stay updated on Rituximab Vs Azathioprine in Eosinophilic Granulomatosis Clinical Trial
Sign up to get notified when there's something new on the Rituximab Vs Azathioprine in Eosinophilic Granulomatosis Clinical Trial page.

Latest updates to the Rituximab Vs Azathioprine in Eosinophilic Granulomatosis Clinical Trial page
- Check6 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded revision note for v3.4.2; removed the government funding lapse notice and the v3.4.1 revision note. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedA site-wide notice about funding status and operations was added, and the site version was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check48 days agoChange DetectedAdds a glossary toggle and new metadata labels such as 'Last Update Submitted that Met QC Criteria' and 'Last Update Posted', updates the revision to v3.4.0, and removes/edits older metadata like 'Last Update Submitted that met QC Criteria' and 'Revision: v3.3.4'.SummaryDifference0.3%

- Check55 days agoChange DetectedThe study record removes a large block of indexing terms and metadata from the page, but the essential content such as the study title, conditions, locations, and eligibility details remains available.SummaryDifference19%

- Check62 days agoChange DetectedMinor site version update observed: Revision: v3.3.4 was added and Revision: v3.3.3 was removed, with no observed changes to study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Rituximab Vs Azathioprine in Eosinophilic Granulomatosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rituximab Vs Azathioprine in Eosinophilic Granulomatosis Clinical Trial page.